Showing results (351-360 of 470) with videos related to
Sort By:
Pageof 47
Journal of Surgical Oncology|December 1, 1993
Response with combined modality treatment in childhood rhabdomyosarcomaN S Raje, S R Rao, S J Vaidya, et al.Ejhaem|February 23, 2023
Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomasJean-Pierre Obeid, Susan M Hiniker, Joseph Schroers-Martin, et al.British Journal of Haematology|May 7, 2015
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesAndrew W Roberts, Ranjana H Advani, Brad S Kahl, et al.Blood|April 19, 2012
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantationAjay K Gopal, Radhakrishnan Ramchandren, Owen A O'Connor, et al.American Journal of Clinical Pathology|November 16, 2017
KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell LymphomasChristian A Kunder, Giovanna Roncador, Ranjana H Advani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin LymphomaAndrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.Blood|June 20, 2013
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experienceDaryl Tan, Sandra J Horning, Richard T Hoppe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapyPurvish M Parikh, Ashok Vaid, Suresh H Advani, et al.Leukemia & Lymphoma|April 7, 2000
A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 studyF J Giles, J Shan, S Chen, et al.Pageof 47